Guangdong Raynovent Biotech Co., Ltd. (China)

Homepage: raynovent.com

Alternate names: Guangdong Raynovent Biotech, Guangdong Raynovent Biotech Co., Ltd., Guangdong Raynovent Biotechnology Co., Ltd., Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd., Guangdong Zhongsheng RuiChuang Biotechnology Co., Ltd., RAYNOVENT Co., Ltd.

ROR: 01e43vr22

OpenAlex ID: I4405267154

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

2024 · Xiaoxin Chen, Xiaodong Huang, et al. · Nature Microbiology · 94

Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

2024 · Zifeng Yang, Zhengtu Li, et al. · The Lancet Infectious Diseases · 39

Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial

2025 · Zifeng Yang, Yangqing Zhan, et al. · The Lancet Respiratory Medicine · 28

Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial

2023 · Bei Wang, Hai-jun Li, et al. · EClinicalMedicine · 28

Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy

2020 · Yuqin Yao, Zhuowei Liu, et al. · Acta Pharmaceutica Sinica B · 25

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

2023 · Yue Hu, Haijun Li, et al. · Nature Communications · 24

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

2021 · Yue Hu, Haijun Li, et al. · Expert Opinion on Investigational Drugs · 20

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitor

2023 · Xiaoxin Chen, Xiaodong Huang, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 19

Single‐Dose Tolerability and Pharmacokinetics of Onradivir in Chinese Patients with Hepatic Impairment and Healthy Matched Controls

2024 · Cuiyun Li, Haijun Li, et al. · The Journal of Clinical Pharmacology · 8

Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19

2024 · Kun Wang, Haijun Li, et al. · Frontiers in Pharmacology · 8

Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis

2019 · Zhigan Jiang, Xing Liu, et al. · ACS Medicinal Chemistry Letters · 8

Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants

2025 · Yue Hu, Haijun Li, et al. · Antimicrobial Agents and Chemotherapy · 7

Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2

2023 · Xiaoxin Chen, Peng Li, et al. · Bioorganic & Medicinal Chemistry Letters · 7

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

2021 · Xiaoxue Zhu, Min Wu, et al. · Expert Opinion on Investigational Drugs · 7

Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure–response approach

2024 · Haijun Li, Yue Hu, et al. · European Journal of Pharmaceutical Sciences · 5

Pharmacokinetics, safety, and tolerability of onradivir in participants with severe renal impairment and matched healthy control participants

2025 · Haijun Li, Xiali Yang, et al. · Antimicrobial Agents and Chemotherapy · 4

Single-dose tolerability and pharmacokinetics of leritrelvir in Chinese patients with hepatic impairment and healthy matched controls

2024 · Cuiyun Li, Jiajia Mai, et al. · Antimicrobial Agents and Chemotherapy · 4

Pharmacokinetic insights of onradivir in influenza treatment to inform pediatric dosing selection in clinical trial

2025 · Haijun Li, Kun Wang, et al. · Drug Metabolism and Disposition · 3

Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study

2022 · Yue Hu, Hai Jun Li, et al. · Journal of Hepatology · 1

Characterization and phylogenetic analysis of the complete mitochondrial genome of the human pathogenic fungus Cryptococcus sp. (Tremellales: Cryptococcaceae)

2019 · Yue Chen, Xiaorong Sun, et al. · Mitochondrial DNA Part B · 1

Efficacy and Safety of Bilpatide, a Bi-weekly GIP/GLP-1 Receptor Agonist, in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

2026 · Linong Ji, Leili Gao, et al. · Research Square

ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis

2026 · Miao Liu, Zhuowei Liu, et al. · Biochemical and Biophysical Research Communications

Pharmacokinetics, Safety, and Exploratory Efficacy of Onradivir in Children with Acute Uncomplicated Influenza: A Multicenter, Dose-Ranging, Phase 2 Study

2026 · Qiang Qin, Chunying Ma, et al. · Infectious Diseases and Therapy

Bioavailability of a novel anti-influenza agent, onradivir granules, in healthy Chinese adults: a first-in-human study

2026 · Xiaoyi Yi, Yuting Liu, et al. · Frontiers in Pharmacology

Enhanced Target Binding by Leritrelvir Restores Dimerization of M pro Mutants and Mitigates Drug Resistance

2026 · Xiaodong Huang, Petr Kuzmič, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Works count: 32

Citation count: 1,057